Study of a new injection for autoimmune diseases
Treatments studied
Part of Immune system & allergy clinical trials.
This study tests an investigational drug called KSVCBD for people with certain autoimmune diseases that haven't improved with standard treatments. It aims to see if the drug is safe and if it can help reduce symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been diagnosed with one of the listed autoimmune diseases that is moderate to severe and hasn't responded to usual treatments.
- Your organs are functioning well enough to participate.
- You agree to use contraception as required by the study.
- You are willing to follow the study procedures and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial is testing an experimental injection called JY231 for people with certain autoimmune diseases like lupus and scleroderma that haven't improved with standard treatments. The aim is to see if this treatment can reduce disease activity and improve symptoms.
This trial tests an experimental injection (called WGb-0301) to see if it can help people with autoimmune diseases like lupus or scleroderma that have not improved with usual treatments. The goal is to find a new option for those who have run out of standard therapies.
This study tests a new investigational drug (called ATG-201) for people with autoimmune diseases. It aims to see if the drug is safe and how it works in the body.
This trial tests whether an investigational drug called KSVCBD can safely reduce relapses in people with neuromyelitis optica spectrum disorder (NMOSD). If you have had at least one relapse in the past year and meet other criteria, you may be able to join.
This study tests a new injectable medicine (SG301) for people with lupus (SLE) whose current treatments are not working well enough or cause side effects. It aims to see if this targeted therapy can better control lupus symptoms.
This trial tests an experimental cell therapy called KSVCBD for people with B-cell non-Hodgkin's lymphoma that has come back or not responded to standard treatments. The therapy targets two proteins (CD19 and BCMA) on cancer cells to help the immune system fight the disease.
Hear when a new Autoimmune Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.